The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing models are anticipated to drive the market. However, issues related to the incorporation of organoids into existing workflows and dearth of skilled professionals are likely to pose a negative impact on the market growth. Organoids are tiny, self-organized, three-dimensional tissue cultures that are derived from stem cells.Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like producing only certain types of cells.
Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters. Organoids are microscopic and self-organizing 3D structures, which are grown from stem cells in vitro.They review various structural and functional characteristics of their in vivo counterpart organs.
This multipurpose technology has led to the development of several novel human cancer models.It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas.
Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids.Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications.
Also, recent studies have proved that organoids have a place in personalized medicine approaches. The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies.Over the past few decades, organoids have been generated from diverse human cancers, related to breast, colon, pancreas, prostate, bladder, and liver.
Studies involving these models are increasing knowledge of the etiology and features of these malignancies.Due to constant advancements, in the current scenario, tumoroid lines are increasingly being passed in vitro, which opens up new paths for a range of downstream applications.
Moreover, 3D-based cultures offer added advantages over the conventional 2D cancer-derived cell lines.Further, research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients.
As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is projected to propel the global organoids market during the forecast period. Type Insights Based on type, the global organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others.In 2019, the intestine segment held the largest market share.
This segment is also expected to dominate the market in 2027 as various experimental techniques have also been developed in parallel with, and applied to, intestinal organoid cultures with a scientifically synergistic effect. Moreover, the kidney segment is anticipated to grow at the fastest rate during the forecast period.
Application Insights Based on application, the global organoids market is segmented into developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others.In 2019, the developmental biology segment held the largest market share in the organoids market.
This segment is also expected to dominate the market by 2027 as it is considered a primary investigative research tool of the human developmental biology. Moreover, organoids derived from embryonic stem cells offer complete understanding of the embryonic process development and insights on development of the stem cells.
Source Insights In terms of source, the global organoids market is segmented into pluripotent stem cells and organ-specific adult stem cells.In 2019, the pluripotent stem cells segment held the largest market share.
This segment is also expected to dominate the market during the forecast period as induced pluripotent stem cells are considered an important resource for regenerative medicine to replace diseased or damaged tissues. Moreover, induced pluripotent stem cells have numerous biomedical applications in basic research, drug screening, toxicological studies, disease modeling, and cell therapy. Major primary and secondary sources included in the report are STEMCELL Technologies, Inc.; Cellesce Ltd.; Hubrecht Organoid Technology; Definigen; 3Dnamics, Inc.; Organoid Therapeutics; PeproTech, Inc.; Thermo Fisher Scientific; Corning Incorporated (Life Sciences); and Merck KGgA.
Our reports have been used by over 10K customers, including:
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The South and Central America nurse call systems market is expected to reach US$ 200.11 million by 2027 from US$ 87.23 million in 2019. The market is estimated to grow at a CAGR of 10.8% from 2020-2027. The growth of the South and Central America nurse call systems market is driven by the growing incidence of Alzheimer’s disease and dementia...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Step by step: An aging US population and a rising prevalence of diabetes are expected to boost industry demand Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and the...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Healthy future: Despite the mounting likelihood of new regulation, industry revenue will likely grow Abstract Cryogenic Biobanking Services Since the landmark scientific achievement of human genome sequencing in 2003, the Cryogenic Biobanking Services industry is increasingly viewed as the link between...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.